Clinical Trial Update: Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose rituximab for efficacy and safety in refractory myasthenia gravis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: First Affiliated Hospital, Sun Yat-Sen University | Conditions: Refractory Myasthenia Gravis, Rituximab | Phase 3 | Status: UNKNOWN